The American Society for Clinical Oncology annual meeting doesn't start until the end of this month, but investors will get a little sneak peek of what to expect when abstracts for the meeting are released at 5 p.m. Eastern on Wednesday.
In the video below, senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss what they're looking forward to seeing at ASCO, including AstraZeneca's (NYSE:AZN) phase 2 data for its PARP inhibitor olaparib used alone or in combination with cediranib in patients with ovarian cancer, Johnson & Johnson (NYSE:JNJ) and Pharmacyclics' (UNKNOWN:PCYC.DL) phase 3 data testing Imbruvica verse GlaxoSmithKline's (NYSE:GSK) Arzerra in elderly CLL patient, Incyte's (NASDAQ:INCY) data on Jakafi in pancreatic cancer, and others.
Brian Orelli has no position in any stocks mentioned. David Williamson owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.